Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207322 · ClinicalTrials.gov registry record · NA
Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield)
A NA study of Complication of Transplant, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT02207322: Completed NA study of Complication of Transplant, sponsored by Massachusetts General Hospital.
NCT02207322 is a NA study of Complication of Transplant that has completed, run by Massachusetts General Hospital. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207322, a NA study of Complication of Transplant, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to assess whether early integration of palliative and supportive care services in care of patients hospitalized for hematopoietic stem cell transplantation (HSCT) can improve patients' and family caregivers' quality of life and mood.
Primary Outcome
Compare quality of life (QOL) (FACT-BMT) scores at week-2 (day+5 for autologous, day +8 for myeloablative or reduced intensity allogeneic HSCT) adjusting for baseline QOL scores between the study arms. Score range 0-164 with higher scores indicating better quality of life
Conditions Studied
Interventions
- OTHER transplant with early palliative care
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-08 |
| Phase | NA |
What the finished NCT02207322 record still lists
NCT02207322 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Complication of Transplant appearing as the primary indexed condition, and to 1 intervention - of which transplant with early palliative care is the first listed.
NCT02207322 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02207322 about?
NCT02207322 is a clinical study titled "Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield)". The main purpose of this study is to assess whether early integration of palliative and supportive care services in care of patients hospitalized for hematopoietic stem cell transplantation (HSCT) can improve patients' and family caregivers' quality of life and mood.
What is the current status of trial NCT02207322?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2014-08. Estimated completion is 2017-08.
What conditions does trial NCT02207322 study?
This clinical trial studies the following conditions: Complication of Transplant.
What interventions are being tested in trial NCT02207322?
The interventions under investigation include: transplant with early palliative care (OTHER).
Who is sponsoring clinical trial NCT02207322?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02207322 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02207322's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia